The United States Food and Drug Administration (USFDA) has concluded an inspection at Solara Active Pharma Sciences’ multiproduct manufacturing facility at Cuddalore. The Agency, with its designated investigators, inspected the Cuddalore facility between July 31, 2023 - August 04, 2023. The inspection established that the facility is in an ‘Acceptable State of Compliance’ with Zero Form 483 inspectional observations from the Agency.
With this successful inspection outcome, the current inspection classification of Cuddalore site shall be reinstated to NAI (No Action Indicated). This facility has also successfully completed the regulatory inspections carried out by the World Health Organization (WHO) between January 23 - 26, 2023 and EU-GMP Inspection carried out jointly by the ‘State Institute for Drug Control (SUKL), Ministry of Health of the Czech Republic’ and ‘National Authority of Medicines and Health Products (INFARMED), Portugal’ between February 07 - 09, 2023.
Solara Active Pharma Sciences is a young, dynamic, entrepreneurial and customer oriented API manufacturer.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1681.15 |
| Dr. Reddys Lab | 1223.50 |
| Cipla | 1239.75 |
| Zydus Lifesciences | 945.55 |
| Lupin | 2315.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: